People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move ...

The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...

This week's stock market saw the S&P 500 rise 3.4%, fueled by positive inflation data and strong earnings reports.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Timing is everything for many things in life — including when to take medication like metformin, sold under the brand names ...

After a fintech startup recently lost its users funds, it is hard to find sympathy for tech companies seeking loosened ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.